|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||9.6800 - 10.9020|
|52 Week Range||2.2000 - 12.5250|
|Beta (3Y Monthly)||2.00|
|PE Ratio (TTM)||88.19|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sales of marijuana in Colorado continue to climb, and that's good news for new marijuana markets, including California and Canada.
CORAL GABLES, FL / ACCESSWIRE / October 19, 2018 / Even withCanadian inflation and retail sales data coming in weaker than expected, market watchers predicted the Bank of Canada still would boost interest rates again next week to in line with a stronger economy. A number of stock market sectors have offered more potential heading into Friday's session with 3 stocks to watch, in particular. Premier Health Group, Inc. (PHGI.CN), is currently reviewing a pipeline of strategicacquisitions and scouting new locations and expects to close on two of these opportunities in Q4-2018.
A very intriguing biopharmaceutical company we have discovered is Propanc Biopharma, Inc. (PPCB). PPCB's lead product PRP was granted Orphan Drug Designation by the FDA for the indication of pancreatic cancer. PPCB is completing the manufacturing necessary for PRP to advance into clinical trials.
TSX: ACB EDMONTON , Oct. 18, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt : 21P; WKN: A1C4WM), announced today that it has filed an ...
Investorsare looking to cash in on a new market are seeing first hand, an industry that generated $8.5 billion on legalmarijuana in the U.S. last year and which is estimated to grow to $23.4 billion in 2022, according to Arcview Market Research and BDS Analytics. PremierHealth Group, Inc. (PHGI.CN), among other things, is targeting acquisitions of clinics, technology and patients in addition to cannabis clinic(s) and partnerships. PremierHealth Group, Inc. (PHGI.CN) completed a CAD $3.55 million financing in August and $1 million was used for the acquisition of HealthVue.
HENDERSON, NV / ACCESSWIRE / October 18, 2018 / Several stocks have caught our eye this week, which we have highlighted below.Propanc Biopharma, Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors, is the one we’re most excited about. PPCB had a massive run from late August through early September exploding from $0.0039 - a high of $0.288 which represented a gain of over 7000%.The company also has a 52 week high of $0.77.If this is your first time hearing about PPCB start doing your own due diligence immediately.The FDA granted PPCB Orphan Drug Designation for its lead product PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
Tilray (TLRY) stock gained ~11.7% on October 15 to $165 per share. Tilray has been a favorite for speculators, and the stock has experienced wild swings as we saw in September. As of October 15, Tilray was the most valuable cannabis company (HMMJ), ahead of Canopy Growth (WEED) (CGC) and Aurora Cannabis (ACB) (ACBFF). Let’s look at analysts’ recommendations and price targets in October.
TSX: ACB EDMONTON , Oct. 18, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt : 21P; WKN: A1C4WM), announced today that its common shares ...
Following years of debate, adults can begin buying marijuana for recreational use today. Here's what you need to know.
TSX: ACB EDMONTON , Oct. 17, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt : 21P; WKN: A1C4WM) applauds the federal government's ...
Canada on Wednesday became the first industrialized nation to legalize recreational use of marijuana – but at least one major investor still isn't convinced that pot stocks are a good bet.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.
All of the major cannabis stocks fell the day before recreational cannabis goes on sale in Canada for the first time. The Horizons Marijuana Life Sciences ETF (HMMJ) lost almost 4.7% during the day. In contrast, the overall market was in positive territory with the TSE Composite Index rising by 1.1% and the S&P 500 Index rising by 2.2% on October 16.
Aurora Cannabis (ACB) (ACBFF) stock rose by 9.9% to its highest level of 15.1 Canadian dollars on October 15. With just one more day until recreational cannabis will be sold legally in Canada, investors (HMLSF) are hopeful that Aurora Cannabis will emerge as a strong player. Overall, the current consensus analyst recommendation for Aurora Cannabis in October is a “buy,” which remained unchanged from September.
Softgel Sales License Granted at Aurora Vie - New Licenses Significantly Increase Product Availability for Medical and Adult Consumer-Use Markets TSX: ACB EDMONTON , Oct. 17, 2018 /CNW/ - Aurora Cannabis ...
WKN: A1C4WM), is proud to celebrate consumer legalization by commending governments of all levels for their commitment to bringing an end to the prohibition of cannabis for adult consumer use, and acknowledging the decades of activism and effort that have led to this moment. With retail sales beginning in provinces across the country today, Canada is the first G20 country to take this historic, transformative step. "It's a proud day to be Canadian," said Aurora CEO Terry Booth.
TSX: ACB EDMONTON , Oct. 17, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQX: ACBFF) (Frankfurt : 21P; WKN: A1C4WM) announced today that the Company ...
HENDERSON, NV / ACCESSWIRE / October 16, 2018 / Monday investors were reminded that hemp companies are a big part of the cannabis craze when Canopy Growth Corp. announced a deal to buy Ebbu Inc., a Colorado-based hemp researcher, in a stock-and-cash deal worth more than $425 million. Under the agreement, Canopy will pay $25 million in cash and issue 6,221,210 shares to Ebbu. Chineseinvestors.com Inc. (CIIX) is our favorite of the lot.
Without a doubt, Canopy Growth (CGC)(WEED) has been one of the hottest cannabis stocks on the market (MJ). The company is one of the most valuable companies, ahead of Aurora Cannabis (ACB) (ACBFF) and Aphria (APHQF). The overall consensus recommendation for Canopy Growth in October is a “buy.” As the above chart shows, two analysts maintained a “strong buy” on the stock, while five analysts maintained a “buy” recommendation on the stock in the current month.
President Trump has the intentions to work towards legalizing medical marijuana on a federal level following next month's midterm races, Rep. Dana Rohrabacher, California Republican, stated this past Thursday. Next Green Wave (NGW) went public this month on the Canadian Stock Exchange. Next Green Wave is composed of industry experts having produced global award-winning seeds and plants under the brand Loud Seeds.
Traditional players have shown a great deal of interest in forming partnerships with cannabis companies, and Aphria (APHQF) was recently reported to be in talks with tobacco giant Altria. The overall consensus analyst recommendation for Aphria in October was a “buy,” which was unchanged from the previous month. Overall, analysts remained bullish on Aphria in October for the next-12-month period.
NEW YORK, NY / ACCESSWIRE / October 16, 2018 / U.S. markets failed to remain in the green on Monday as a technology sector selloff erased earlier gains. Tech giants Netflix and Apple both dropped more ...
Launched today under the brand Aurora Cloud, the first products released contain over 550mg of CBD and less than 30mg of THC, making them the only vape-ready CBD products legally available in Canada. This is the first of a broader line of full-spectrum cannabinoid-based, vape ready cartridge products the Company intends to launch in the future. As the only licenced producer to have successfully navigated the technical and regulatory challenges required to bring this product to market, Aurora will initially focus on distribution to medical patients.
The cannabis business has been on fire lately, and there’s one area in the space that could still have serious potential to heat up: edibles, according to a new report by Arcview Market Research.